Figure 2.
The impact of CMV reactivation on NRM among the patients in each group by a landmark analysis at day 100.(A) Group1 (low reactivation risk group). (B) Group 2 (intermediate risk group). (C) Group 3 (high risk group).
The impact of CMV reactivation on NRM among the patients in each group by a landmark analysis at day 100.(A) Group1 (low reactivation risk group). (B) Group 2 (intermediate risk group). (C) Group 3 (high risk group).